capecitabine + fluorouracil + ivosimab + leucovorin + oxaliplatin

This drug is a **combination chemotherapy regimen** consisting of capecitabine, fluorouracil, ivosimab, leucovorin, and oxaliplatin. These agents are frequently used in the treatment of metastatic and advanced colorectal cancer and other gastrointestinal cancers. - **Capecitabine** is an oral prodrug that is enzymatically converted to fluorouracil (5-FU) primarily within tumor tissue, where it acts as an antimetabolite to inhibit DNA synthesis and slow tumor growth[9][1][2]. - **Fluorouracil (5-FU)** is a classic pyrimidine analog antimetabolite that disrupts DNA synthesis by inhibiting thymidylate synthase, leading to tumor cell death[2][6]. - **Leucovorin** is used as a biomodulator to enhance the cytotoxic effects of 5-FU by stabilizing the 5-FU-thymidylate synthase complex, increasing inhibition of DNA synthesis[2][6]. - **Oxaliplatin** is a platinum-based antineoplastic agent that causes DNA crosslinking, leading to apoptosis of cancer cells[1][3][7]. - **Ivosimab** is not a currently recognized or approved monoclonal antibody in standard oncology practice as of the knowledge cutoff or found in provided literature, suggesting it may be a novel, investigational, or misnamed compound. This combination employs multiple mechanisms—**antimetabolite inhibition, biomodulation, and DNA crosslinking**—to target rapidly dividing tumor cells. Such combinations (particularly without ivosimab, with regimens like CAPOX/XELOX or FOLFOX) are standard in first-line and advanced colorectal cancer therapy, offering synergistic efficacy and sometimes improved tolerability profiles[1][2][3][4][6][7].